{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:45:55Z","timestamp":1792856755146,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Japan Agency for Medical Research and Development","award":["JP19ek0109268"],"award-info":[{"award-number":["JP19ek0109268"]}]},{"name":"the Ministry of Health, Labour and Welfare of Japan awarded to the study Group on Pulmonary Disorders, Scientific Research\/Research on intractable diseases","award":["H29-023"],"award-info":[{"award-number":["H29-023"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-granulocyte\u2013macrophage colony-stimulating factor autoantibody (GMAb) has been recognized as a diagnostic biomarker for autoimmune pulmonary alveolar proteinosis (aPAP). The aims of this study were to know the incidence of increased level of serum GMAb in granulomatous lung diseases (sarcoidosis and hypersensitivity pneumonitis [HP]) and to clarify the role of GMAb. Consecutive individuals diagnosed with sarcoidosis (n\u2009=\u200992) and HP (n\u2009=\u200945) at National Hospital Organization Kinki-Chuo Chest Medical Center were retrospectively analyzed. We measured serum GMAb levels at the diagnosis. Cut-off values of GMAb discriminating aPAP (n\u2009=\u2009110) from healthy controls (n\u2009=\u200931) were determined by receiver operating characteristic (ROC) curve analysis. We compared the clinical features of sarcoidosis and HP patients with GMAb levels above the cut-off value (\u201cElevated-GMAb\u201d) with those of patients whose GMAb levels below the cut-off value (\u201cLow-GMAb\u201d). Radiological and pathological findings in elevated-GMAb patients were re-evaluated to elucidate the role of GMAb in granulomatous lung diseases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Analysis of ROC indicated a sensitivity and specificity of 100% at GMAb level of 3.33\u00a0\u03bcg\/mL for discriminating aPAP from healthy controls (area under curve\u2009=\u20091.000, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The percentages of elevated-GMAb sarcoidosis and HP patients were 5.4% (n\u2009=\u20095) and 11.1% (n\u2009=\u20095), respectively. The number of comorbid sarcoidosis and HP patients with aPAP was two and one, respectively. Elevated-GMAb sarcoidosis patients presented with significantly higher serum levels of Krebs von den Lungen (KL)-6, surfactant protein-D (SP-D), lactate dehydrogenase, and the requirement of systemic corticosteroid therapy. Elevated-GMAb HP patients demonstrated older age, higher serum KL-6, SP-D, carcinoembryonic antigen, and cytokeratin fragment 21-1 levels, and a higher percentage of lymphocytes in bronchoalveolar lavage than low-GMAb patients. A subset of patients presented with radiological and pathological findings characteristic of aPAP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We demonstrated the percentage of elevated-GMAb sarcoidosis and HP patients who presented with several features suggestive of aPAP. Elevated-GMAb sarcoidosis and HP patients without definitive\u00a0aPAP diagnosis may have subclinical or early-stage aPAP and may not necessarily indicate false positives. Upon diagnosis of sarcoidosis or HP, measurement of GMAb may be useful in detecting possible comorbidity of subclinical or early-onset aPAP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01546-x","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T12:03:11Z","timestamp":1601380991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Clinical significance of serum anti-granulocyte\u2013macrophage colony-stimulating factor autoantibodies in patients with sarcoidosis and hypersensitivity pneumonitis"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1550-475X","authenticated-orcid":false,"given":"Kanako","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2222-0683","authenticated-orcid":false,"given":"Toru","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Hatsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikatoshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Akira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-874X","authenticated-orcid":false,"given":"Yoshikazu","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"1546_CR1","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1056\/NEJMra023226","volume":"349","author":"BC Trapnell","year":"2003","unstructured":"Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527\u201339.","journal-title":"N Engl J Med"},{"key":"1546_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1164\/rccm.200708-1271OC","volume":"177","author":"Y Inoue","year":"2008","unstructured":"Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med. 2008;177:752\u201362.","journal-title":"Am J Respir Crit Care Med"},{"key":"1546_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S2213-2600(18)30043-2","volume":"6","author":"A Kumar","year":"2018","unstructured":"Kumar A, Abdelmalak B, Inoue Y, Culver DA. Pulmonary alveolar proteinosis in adults: pathophysiology and clinical approach. Lancet Respir Med. 2018;6:554\u201365.","journal-title":"Lancet Respir Med"},{"key":"1546_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1084\/jem.190.6.875","volume":"190","author":"T Kitamura","year":"1999","unstructured":"Kitamura T, Tanaka N, Watanabe J, Kanegasaki S, Yamada Y, Nakata K. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte\/macrophage colony-stimulating factor. J Exp Med. 1999;190:875\u201380.","journal-title":"J Exp Med"},{"key":"1546_CR5","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1164\/ajrccm.162.2.9910032","volume":"162","author":"T Kitamura","year":"2000","unstructured":"Kitamura T, Uchida K, Tanaka N, Tsuchiya T, Watanabe J, Yamada Y, et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Resp Crit Care Med. 2000;162:658\u201362.","journal-title":"Am J Resp Crit Care Med"},{"key":"1546_CR6","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1182\/blood-2008-05-155689","volume":"113","author":"K Uchida","year":"2009","unstructured":"Uchida K, Nakata K, Suzuki T, Luisetti M, Watanabe M, Koch DE, et al. Granulocyte\/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood. 2009;113:2547\u201356.","journal-title":"Blood"},{"key":"1546_CR7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1136\/thx.2005.054171","volume":"61","author":"FC Lin","year":"2006","unstructured":"Lin FC. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax. 2006;61:528\u201334.","journal-title":"Thorax"},{"key":"1546_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1165\/rcmb.2002-0023OC","volume":"27","author":"TL Bonfield","year":"2002","unstructured":"Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Resp Cell Mol Biol. 2002;27:481\u20136.","journal-title":"Am J Resp Cell Mol Biol"},{"key":"1546_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1165\/ajrcmb\/3.3.245","volume":"3","author":"A Itoh","year":"1990","unstructured":"Itoh A, Yamaguchi E, Kuzumaki N, Okazaki N, Furuya K, Abe S, et al. Expression of granulocyte macrophage colony-stimulating factor mRNA by inflammatory cells in the sarcoid lung. Am J Resp Cell Mol Biol. 1990;3:245\u20139.","journal-title":"Am J Resp Cell Mol Biol"},{"key":"1546_CR10","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cyto.2012.12.016","volume":"61","author":"KC Patterson","year":"2013","unstructured":"Patterson KC, Franek BS, M\u00fcller-Quernheim J, Sperling AI, Sweiss NJ, Niewold TB. Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and non-fibrotic pulmonary disease. Cytokine. 2013;61:906\u201311.","journal-title":"Cytokine"},{"key":"1546_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1164\/rccm.200301-137OC","volume":"168","author":"Y Lacasse","year":"2003","unstructured":"Lacasse Y, Selman M, Costabel U, Dalphin JC, Ando M, Morell F, et al. Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2003;168:952\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1546_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1164\/rccm.200912-1800ED","volume":"181","author":"U Costabel","year":"2010","unstructured":"Costabel U, Nakata K. Pulmonary alveolar proteinosis associated with dust inhalation. Am J Respir Crit Care Med. 2010;181:427\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"1546_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1183\/09031936.00092910","volume":"37","author":"H Ishii","year":"2011","unstructured":"Ishii H, Tazawa R, Kaneko C, Saraya T, Inoue Y, Hamano E, et al. Clinical features of secondary pulmonary alveolar proteinosis: pre-mortem cases in Japan. Eur Respir J. 2011;37:465\u20138.","journal-title":"Eur Respir J"},{"key":"1546_CR14","doi-asserted-by":"publisher","unstructured":"Mirchandani AS, Thomson NC. First presentation of breathlessness: pulmonary alveolar proteinosis with sarcoid. B39. Am J Respir Crit Care Med. 2010;A2948. https:\/\/doi.org\/10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2948.","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2948"},{"key":"1546_CR15","first-page":"90","volume":"33","author":"EB Boerner","year":"2016","unstructured":"Boerner EB, Costabel U, Wessendorf TE, Theegarten D, Hetzel M, Drent M, et al. Pulmonary alveolar proteinosis: another autoimmune disease associated with sarcoidosis? Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:90\u20134.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"1546_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1620\/tjem.243.77","volume":"243","author":"M Yamasue","year":"2017","unstructured":"Yamasue M, Nureki S-I, Usagawa Y, Ono T, Matsumoto H, Kan T, Kadota JI. Elevated serum anti-GM-CSF antibodies before the onset of autoimmune pulmonary alveolar proteinosis in a patient with sarcoidosis and systemic sclerosis. Tohoku J Exp Med. 2017;243:77\u201383.","journal-title":"Tohoku J Exp Med"},{"key":"1546_CR17","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ccr3.2068","volume":"7","author":"Y Tanaka","year":"2019","unstructured":"Tanaka Y, Shirai T, Asada K, Muramatsu A, Katsumata M, Suda T. Autoimmune pulmonary alveolar proteinosis in a patient with sarcoidosis. Clin Case Rep. 2019;7:731\u20134.","journal-title":"Clin Case Rep"},{"key":"1546_CR18","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3853-19","author":"T Arai","year":"2020","unstructured":"Arai T, Kasai T, Shimizu K, Kawahara K, Katayama K, Sugimoto C, et al. Autoimmune pulmonary alveolar proteinosis complicated with sarcoidosis: clinical courses and serum levels of anti-granulocyte-macrophage colony-stimulating factor autoantibody. Intern Med. 2020. https:\/\/doi.org\/10.2169\/internalmedicine.3853-19.","journal-title":"Intern Med."},{"key":"1546_CR19","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/j.1440-1843.2010.01848.x","volume":"15","author":"H Verma","year":"2010","unstructured":"Verma H, Nicholson AG, Kerr KM, Dempsey OJ, Gibbs AR, Campbell I, et al. Alveolar proteinosis with hypersensitivity pneumonitis: a new clinical phenotype. Respirology. 2010;15:1197\u2013202.","journal-title":"Respirology"},{"key":"1546_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2217\/bmm-2017-0362","volume":"12","author":"M Nishimura","year":"2018","unstructured":"Nishimura M, Yamaguchi E, Takahashi A, Asai N, Katsuda E, Ohta T, et al. Clinical significance of serum anti-GM-CSF autoantibody levels in autoimmune pulmonary alveolar proteinosis. Biomark Med. 2018;12:151\u20139.","journal-title":"Biomark Med"},{"key":"1546_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.rmed.2014.12.012","volume":"109","author":"M Sawahata","year":"2015","unstructured":"Sawahata M, Sugiyama Y, Nakamura Y, Nakayama M, Mato N, Yamasawa H, et al. Age-related and historical changes in the clinical characteristics of sarcoidosis in Japan. Respir Med. 2015;109:272\u20138.","journal-title":"Respir Med"},{"key":"1546_CR22","first-page":"89","volume":"27","author":"H Hiraga","year":"2007","unstructured":"Hiraga H, Yuwai K, Hirose M. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord. 2007;27:89\u2013102.","journal-title":"Jpn J Sarcoidosis Granulomatous Disord"},{"key":"1546_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1164\/rccm.201611-2201PP","volume":"196","author":"M Vasakova","year":"2017","unstructured":"Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196:680\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1546_CR24","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1164\/rccm.201608-1675PP","volume":"196","author":"ML Salisbury","year":"2017","unstructured":"Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017;196:690\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"1546_CR25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1164\/rccm.201710-1986OC","volume":"197","author":"J Morisset","year":"2018","unstructured":"Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, et al. Identification of diagnostic criteria for chronic hypersensitivity pneumonitis: an international modified Delphi Survey. Am J Respir Crit Care Med. 2018;197:1036\u201344.","journal-title":"Am J Respir Crit Care Med"},{"key":"1546_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s11604-020-00932-6","volume":"38","author":"T Tateishi","year":"2020","unstructured":"Tateishi T, Johkoh T, Sakai F, Miyazaki Y, Ogura T, Ichikado K, et al. High-resolution CT features distinguishing usual interstitial pneumonia pattern in chronic hypersensitivity pneumonitis from those with idiopathic pulmonary fibrosis. Jpn J Radiol. 2020;38:524\u201332.","journal-title":"Jpn J Radiol"},{"key":"1546_CR27","unstructured":"Pulmonary alveolar proteinosis. https:\/\/www.nanbyou.or.jp\/wp-content\/uploads\/upload_files\/File\/229-201704-kijyun.pdf. Accessed 16 Aug 2020. (in Japanese)."},{"key":"1546_CR28","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJMoa1816216","volume":"381","author":"R Tazawa","year":"2019","unstructured":"Tazawa R, Ueda T, Abe M, Tatsumi K, Eda R, Kondoh S, et al. Inhaled GM-CSF for pulmonary alveolar proteinosis. N Engl J Med. 2019;381:923\u201332.","journal-title":"N Engl J Med"},{"key":"1546_CR29","doi-asserted-by":"publisher","first-page":"00259","DOI":"10.1183\/23120541.00259-2019","volume":"6","author":"K Nakata","year":"2020","unstructured":"Nakata K, Sugi T, Kuroda K, Yoshizawa K, Takada T, Tazawa R, et al. Validation of a new serum granulocyte\u2013macrophage colony-stimulating factor autoantibody testing kit. ERJ Open Res. 2020;6:00259\u20132019. https:\/\/doi.org\/10.1183\/23120541.00259-2019.","journal-title":"ERJ Open Res"},{"key":"1546_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","author":"J Hutchinson","year":"1999","unstructured":"Hutchinson J. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160:736\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"1546_CR31","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","volume":"357","author":"MC Iannuzzi","year":"2007","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153\u201365.","journal-title":"N Engl J Med"},{"key":"1546_CR32","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1182\/blood-2003-05-1565","volume":"103","author":"K Uchida","year":"2003","unstructured":"Uchida K. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood. 2003;103:1089\u201398.","journal-title":"Blood"},{"key":"1546_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMoa062505","volume":"356","author":"K Uchida","year":"2007","unstructured":"Uchida K, Beck DC, Yamamoto T, Berclaz PY, Abe S, Staudt MK, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med. 2007;356:567\u201379.","journal-title":"N Engl J Med"},{"key":"1546_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12890-015-0085-0","volume":"15","author":"K Akasaka","year":"2015","unstructured":"Akasaka K, Tanaka T, Kitamura N, Ohkouchi S, Tazawa R, Takada T, et al. Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: a retrospective cohort study. BMC Pulm Med. 2015;15:88.","journal-title":"BMC Pulm Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01546-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01546-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01546-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:34:43Z","timestamp":1632872083000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01546-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1546"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01546-x","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"26 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of the NHO Kinki-Chuo Chest Medical Center (KCCMC; Approval number: 735, 6 February 2020).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants provided written, informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"272"}}